Memantine: a comprehensive review of safety and efficacy

Bibliography

• Cooper J, Bloom F, Roth R. The biochemical basis of neuropharmacology. New York: Oxford University Press; 2003
   Google Scholar
• Parsons C, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improved memory by restoration of homeostasis in the glutamate system – too little activation is bad, too much is even worse. Neuropharmacology 2007;53:699-723
   PubMed Web of Science ®Google Scholar
• Charles A, Flippen C, Romero Reyes M, et al. Memantine for the prevention of headache: a retrospective study of 60 cases. J Headache Pain 2007;8:248-50
   PubMed Web of Science ®Google Scholar
• Zdanys K, Tampi R. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008
   PubMedGoogle Scholar
• Anonymous. Approval labeling text for Namenda, United States Food and Drug Administration. 2003. 30 March 2008 [cited October 16, 2003]. Available from: http://www.fda.gov/cder/foi/label/2003/021487lbl.pdf
   Google Scholar
• Periclou A, Venture D, Rao N, et al. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 2006;79:134-43
   PubMed Web of Science ®Google Scholar
• Periclou A, Ventura D, Sherman T, et al. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004;38(9):1389-94
   PubMed Web of Science ®Google Scholar
• Rao N, Chou T, Ventura D, et al. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Clin Ther 2005;27(10):1596-606
   PubMed Web of Science ®Google Scholar
• Shua-Haim J, Smith J, Picard F, et al. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label. crossover, single-centre study. Clin Drug Invest 2008;28(6):361-74
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006;63:49-54
   PubMed Web of Science ®Google Scholar
• Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-72
   PubMed Web of Science ®Google Scholar
• NICE. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). NICE Technology Appraisals (TA) 2007. Available from: http://www.nice.org.uk/nicemedia/pdf/TA111fullversionamendedSept07.pdf
   Google Scholar
• McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;(2):CD003154. DOI:10.1002/14651858.CD003154.pub5
   Google Scholar
• Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348(14):1333-41
   PubMed Web of Science ®Google Scholar
• Tariot P, Farlow M, Grossberg G, et al. Memantine treatment in moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291(3):317-24
   PubMed Web of Science ®Google Scholar
• Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007;24(1):20-7
   PubMed Web of Science ®Google Scholar
• Doody R, Tariot P, Pfeiffer E, et al. Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimer's Dementia 2007;3:7-17
   PubMed Web of Science ®Google Scholar
• Porsteinsson A, Grossberg G, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5(1):83-9
   PubMed Web of Science ®Google Scholar
• Peskind E, Potkin S, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006;14(8):704-15
   PubMed Web of Science ®Google Scholar
• Schneider L. Commentary on “Meta-analysis of six-month memantine trials in Alzheimer's disease.” Wuthering forest plots: distinguishing the forest from the plots. Alzheimer's Dementia 2007;3:18-20
   PubMed Web of Science ®Google Scholar
• Orgogozo J, Rigaud A, Stöffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002;33(7):1834-9
   PubMed Web of Science ®Google Scholar
• Wilcock G, Möbius H, Stöffler A, et al. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002;17(6):297-305
   PubMed Web of Science ®Google Scholar
• Mobius H, Stöffler A. Memantine in vascular dementia. Int Psychogeriatr 2003;15(Suppl 1):207-13
   PubMedGoogle Scholar
• Jellinger K. Morphologic diagnosis of “vascular dementia” – a critical update. J Neuro Sci 2008;270:1-12
   PubMed Web of Science ®Google Scholar
• Kavirajan H, Schneider L. Efficacy and adverse effects of cholinesterase inhibitors in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:782-92
   PubMed Web of Science ®Google Scholar
• Ferris S, Schneider L, Farmer M, et al. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI). Int J Geriatr Psychiatry 2007;22:448-55
   PubMed Web of Science ®Google Scholar
• Petersen R. Mild cognitive impairment: current research and clinical implications. Semin Neurol 2007;27(1):22-31
   PubMed Web of Science ®Google Scholar
• Schiffito G, Navia B, Yiannoutsos C, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 2007;21(14):1877-86
   PubMed Web of Science ®Google Scholar
• Diehl-Schmid J, Förstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry 2008;23:754-9
   PubMed Web of Science ®Google Scholar
• Ondo W, Mejia N, Hunter C. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord 2007;13:453-4
   PubMed Web of Science ®Google Scholar
• Krystal JH, Petrakis IL, Mason G, et al. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther 2003;99(1):79-94
   PubMed Web of Science ®Google Scholar
• Krupitsky EM, Zeznanova O, Masalov D, et al. Effect of alcohol on cue-induced craving in recovering alcohol-dependent patients. Am J Psychiatry 2007;164(3):519-23
   PubMed Web of Science ®Google Scholar
• Evans S, Levin F, Brooks D, et al. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcoholism. Clin Exp Res 2007;31(5):775-82
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Rudenko AA, Burakov AM, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 2007;31(4):604-11
   PubMed Web of Science ®Google Scholar
• Comer S, Sullivan M. Memantine produced modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology 2007;193:235-45
   PubMed Web of Science ®Google Scholar
• Bisaga A, Comer SD, Ward AS, et al. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology 2001;157:1-10
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Masalov D, Burakov A, et al. A pilot study of memantine effects on protracted withdrawal (syndrome of anhedonia) in heroin addicts. Addict Disord Treat 2002;1:143-46
   Google Scholar
• Collins E, Ward A, McDowell D, et al. The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. Behav Pharmacol 1998;9:587-98
   PubMed Web of Science ®Google Scholar
• Collins E, Vosburg S, Ward A, et al. Memantine increases cardiovascular but not behavioral effects of cocaine in methadone-maintained humans. Pharmacol Biochem Behav 2006;83:47-55
   PubMed Web of Science ®Google Scholar
• Thuerauf N, Lunkenheimer J, Lunkenheimer B, et al. Memantine fails to facilitate partial cigarette deprivation in smokers-no role of Memantine in the treatment of nicotine dependency? J Neural Transm 2007;114:351-7
   PubMed Web of Science ®Google Scholar
• Pittenger C, Sanacora G, Krystal J. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 2007;6(2):101-15
   PubMedGoogle Scholar
• Zarate C Jr, Singh J, Quiroz J, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006;163(1):153-5
   PubMed Web of Science ®Google Scholar
• Muhonen L, Lönnqvist J, Juva K, et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008;69:392-9
   PubMed Web of Science ®Google Scholar
• Sanacora G, Zarate C, Krystal J, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7(5):426-37
   PubMed Web of Science ®Google Scholar
• Ongür D, Jensen J, Prescot A, et al. Abnormal glutamatergic neurotransmission and neuronal-Glial interactions in acute mania. Biol Psychiatry [Epub Jul 2 2008]
   Google Scholar
• Teng C, Demetrio F. Memantine may acutely improve cognition and have a mood-stabilizing effect in treatment-resistant bipolar disorder. Rev Bras Psiquiatr 2006;28(3):251-6
   PubMed Web of Science ®Google Scholar
• El Mansari M, Blier P. Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(3):362-73
   PubMed Web of Science ®Google Scholar
• Pasquini M, Biondi M. Memantine for treatment-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1173-5
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Weizman R, Weizman A, et al. Memantine for treatment-resistant OCD. Am J Psychiatry 2005;162(11):2191-2
   PubMed Web of Science ®Google Scholar
• Adamec R. Transmitter systems involved in neural plasticity underlying increased anxiety and defense-implications for understanding anxiety following traumatic stress. Neurosci Biobehav Rev 1997;21(6):755-65
   PubMed Web of Science ®Google Scholar
• Battista M, Hierholzer R, Khouza H, et al. Pilot trial of memantine in the treatment of posttraumatic stress disorder. Psychiatry Interpers Biol Processes 2007;70(2):167-74
   PubMed Web of Science ®Google Scholar
• Krivoy A, Weizman A, Laor L, et al. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: a preliminary study. Eur Neuropsychopharmacol 2008;18(2):117-21
   PubMed Web of Science ®Google Scholar
• Anonymous. A double-blind placebo controlled evaluation of the safety and efficacy of memantine as adjunctive treatment to atypical antipsychotics produces improvement in schizophrenic subjects with residual symptoms. Forest Clinical Trials Registry Unpublished. 13 July 2006 [cited June 16, 2008]. Available from: http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-29_final.pdf
   Google Scholar
• Carroll B, Thomas C, Jayanti K. Letter to the Editor-Amandatine and memantine in catatonic schizophrenia. Ann Clin Psychiatry 2006;18(2):133-4
   PubMedGoogle Scholar
• Carpenter S, Hatchett A, Fuller M. Catatonic schizophrenia and the use of memantine. Ann Pharmacother 2006;40:344-6
   PubMed Web of Science ®Google Scholar
• Thomas C. Letter to the Editor–Memantine and catatonic schizophrenia. Am J Psychiatry 2005;162(3):626
   PubMedGoogle Scholar
• Schaefer M, Leopold K, Hinzpeter A, et al. Memantine-associated reversal of clozapine-induced weight gain. Pharmacopsychiatry 2007;40:149-51
   PubMed Web of Science ®Google Scholar
• Hermanussen M, Tresguerres J. A new anti-obesity drug treatment: first clinical evidence that, antagonising glutamate-gated Ca2+ ion channels with memantine normalises binge-eating disorders. Econ Hum Biol 2005;3:329-37
   PubMedGoogle Scholar
• Owley T, Salt J, Guter S, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolescent Psychopharmacol 2006:517-524
   PubMed Web of Science ®Google Scholar
• Chez M, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in children diagnosed with autism spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 2007;22:574-9
   PubMed Web of Science ®Google Scholar
• Findling R, McNamara N, RJ S, et al. A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit hyperactivity disorder combined type. J Child Adolescent Psychopharmacol 2007;17(1):19-33
   PubMed Web of Science ®Google Scholar
• Sang C, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002;96:1053-61
   PubMed Web of Science ®Google Scholar
• Wiech K, Kiefer R, Töpfner S, et al. A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth Analg 2004;98:408-13
   PubMed Web of Science ®Google Scholar
• Anonymous. Double-blind comparison of memantine and placebo in the treatment of chronic pain in patients with diabetic neuropathy. Forest Clinical Trials Registry Unpublished. [cited 16 June 2008]. Available from: http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-06A_final.pdf
   Google Scholar
• Anonymous. A randomized, double-blind fixed dose study comparing the efficacy a nd safety of daily doses of 40mg, 60mg, and 80mg of memantine in patients with painful diabetic neuropathy. Forest Clinical Trials Registry Unpublished [cited 16 June 2008]. Available from: http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-06C_final.pdf
   Google Scholar
• Anonymous. A randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy and safety of memantine in comparison to gabapentin in patients with post-herpetic neuralgia. Forest Clinical Trials Registry Unpublished [cited 16 June 2008]. Available from: http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-20_final.pdf
   Google Scholar
• Anonymous. A randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy and safety of memantine in comparison to gabapentin in patients with painful diabetic neuropathy. Forest Clinical Trials Registry Unpublished [cited 16 June 2008]. Available from: http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-19_final.pdf
   Google Scholar
• Nikolajsen L, Gottrup H, Kristensen A, et al. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesthesiology 2000;91:960-6
   Google Scholar
• Eisenberg E, Kleiser A, Dortort A, et al. The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study. Eur J Pain 1998;2:321-7
   PubMed Web of Science ®Google Scholar
• Maier C, Dertwinkel R, Mansourian N, et al. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain – results of a randomized double-blinded, placebo-controlled trial. Pain 2003;103:277-83
   PubMed Web of Science ®Google Scholar
• Schley M, Topfner S, Wiech K, et al. Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees. Eur J Pain 2007;11:299-308
   PubMed Web of Science ®Google Scholar
• McLean R, Proudlock F, Thomas S, et al. Congenital nystagmus: randomized, controlled, double-masked trial of memantine/gabapentin. Ann Neurol 2007;61:130-138.
   PubMed Web of Science ®Google Scholar
• Pulido J, Pulido J, Erie J, et al. A role for excitatory amino acids in diabetic eye disease. Exp Diabetes Res 2007
   Google Scholar
• Casson R. Possible role of excitotoxicity in the pathogenesis of glaucoma. Clin Exp Ophthalmol Rev 2006;34(1):54-63
   PubMed Web of Science ®Google Scholar
• Anonymous. ClinicalTrialsgov 2008 [cited 23 June 2008]. Available from: http://www.clinicaltrials.gov/ct2/results?term=memantine
   Google Scholar
• Creeley CE, Wozniak DF, Nardi A, et al. Donepezil markedly potentiates memantine toxicity in the adult rat brain. Neurobiol Aging 2008;29(2):153-67
   PubMed Web of Science ®Google Scholar
• Schneider L. Open label trials and misinformation. Arch Neurol 2006;63(7):1036
   PubMedGoogle Scholar
• Muir K. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006;6:53-60
   PubMed Web of Science ®Google Scholar
• Sloane P, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Ann Rev Public Health 2002;23:213-31
   PubMed Web of Science ®Google Scholar
• James P. Obesity: the worldwide epidemic. Clin Dermatol 2004;22(4):276-80
   PubMed Web of Science ®Google Scholar
• Stovner L, Hagen K. Prevalence, burden, and cost of headache disorders. Curr Opin Neurol 2006;19(3):281-5
   PubMed Web of Science ®Google Scholar
• Quigley H, Broman A. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90(3):262-7
   PubMed Web of Science ®Google Scholar
• Pulido J, Pulido J, Erie J, et al. A role for excitatory amino acids in diabetic eye disease. Exp Diabetes Res Published online 2007 June 25
   Google Scholar
• Bisaga A, Evans S. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (Berl) 2004;172(1):16-24
   PubMed Web of Science ®Google Scholar
• Anonymous. A randomized, double-blind, placebo-controlled, flexible dose study of the safety and efficacy of memantine in comparison to gabapentin in patients with post-herpetic neuralgia. Unpublished [cited 16 June 2008]. Available from: http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-20_final.pdf
   Google Scholar